Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

56.58 +0.24 (+0.43%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,813,757
Open 57.00
Bid (Size) 56.10 (2)
Ask (Size) 57.10 (3)
Prev. Close 56.34
Today's Range 56.07 - 57.08
52wk Range 46.48 - 64.21
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Tempus Signs Strategic Collaboration Agreement With AstraZeneca to Advance Oncology Therapeutics
Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) in which the two companies will work... 
From Business Wire News Releases
TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer 
From Business Wire News Releases

Performance

YTD
+12.00%
+12.00%
1 Month
-9.02%
-9.02%
3 Month
-3.46%
-3.46%
6 Month
+0.59%
+0.59%
1 Year
+7.55%
+7.55%

More News

Read More
Interesting AZN Put And Call Options For January 2022
Tags Stocks
From Market News Video
WHO urges world leaders not to have knee-jerk reaction to new coronavirus variant from South Africa as UK and EU impose travel bans
Tags BNTX AZN MRK
From MarketWatch
Pfizer's COVID-19 Franchise Could Push Revenue Past $100B In 2022: Analyst
Tags AZN SVB Leerink Analyst Ratings
From Benzinga
New Analyses of Two AZD7442 COVID-19 Phase III Trials in High-Risk Populations Confirm Robust Efficacy and Long-Term Prevention
From Business Wire News Releases
On an ugly day for markets, here’s the S&P 500 level investors need to watch closely, says this trader
Tags XE:LHA UAL JWN
From MarketWatch
Got $5,000? These 2 Stocks Could Be Bargain Buys in 2022
Tags MCD MRNA AZN
From Motley Fool
EU Says Decision On J&J COVID-19 Booster Shot Expected 'Within Weeks'
Tags Briefs Biotech MRNA
From Benzinga
LOKELMA® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia
From Business Wire News Releases
AstraZeneca Decides It's OK to Make Money From the Pandemic
Tags AZN Market News Recent Press Releases
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.